Dominik Klaiber

Listed in the internal database as A. Klaiber, this researcher is a clinical investigator involved in multiple randomized, double-blind, placebo-controlled and cross-over experimental medicine studies examining the acute effects of serotonergic and empathogenic compounds. Their work, as represented in the provided study list, spans intravenous DMT, single and combined administration of MDMA and LSD, stereoisomer-specific MDMA investigations (R‑MDMA versus S‑MDMA and racemic MDMA), psilocybin under selective serotonin reuptake inhibitor pretreatment (escitalopram), and a comparative acute-effects study of mescaline, LSD and psilocybin. These trials focus on safety, acute subjective and physiological responses, and implications for anxiety and depressive disorder research using healthy volunteer cohorts.

Klaiber's contributions appear concentrated in early-phase human pharmacology and psychopharmacology of psychedelic compounds, with emphasis on rigorous experimental design (randomized, double-blind, placebo-controlled, cross-over paradigms) and comparative pharmacodynamic characterisation. The available record suggests expertise in acute-effects profiling, drug–drug interaction/pretreatment paradigms, and stereoisomer-specific investigation—work that informs both mechanistic understanding and clinical development pathways for psychedelic-assisted interventions. (Note: the researcher's full given name was not available in the provided materials; please supply the complete first name for a definitive bibliographic record.)